Semaglutide kept its safety profile across chronic kidney disease severity in FLOW
Semaglutide remained broadly tolerable in people with type 2 diabetes and chronic kidney disease enrolled in FLOW, even as kidney function declined. In this prespecified secondary safety analysis, the adverse-event pattern did not fracture into a new risk signal at lower estimated glomerular filtration rate, where clinicians often worry that drug intolerance, frailty, and intercurrent illness will stack together and narrow the margin for treatment.
The trial’s safety readout matters because CKD changes the bedside equation. Patients with lower eGFR commonly carry more comorbidity, take more medications, and face a higher baseline burden of hospitalization, infection, cardiac instability, and treatment discontinuation. A therapy that preserves kidney and cardiovascular benefit but becomes difficult to sustain in advanced CKD would have limited practical value. Here, the overall safety profile stayed consistent across the eGFR spectrum represented in FLOW.
Serious adverse events did not rise as kidney function fell
FLOW was a double-blind, randomized, placebo-controlled trial of subcutaneous semaglutide 1.0 mg once weekly in participants with T2D and CKD, with a primary kidney outcome defined as a 50% or greater eGFR decline, kidney failure, or death from kidney or cardiovascular causes. This analysis focused on safety by baseline eGFR and used systematically collected data on serious adverse events, adverse events leading to treatment discontinuation, and prespecified adverse events of special interest.
Among 3,533 participants, 1,767 received semaglutide and 1,766 received placebo. Serious adverse events were reported less often with semaglutide than with placebo across eGFR strata. In participants with baseline eGFR of 60 or more mL/min/1.73 m2, serious adverse events occurred in 45.1% of the semaglutide group versus 50.4% of the placebo group. In those with baseline eGFR below 30 mL/min/1.73 m2, the corresponding figures were 56.4% and 60.4%.
A one-sentence reading of the data stands out clearly: advanced CKD did not uncover a hidden semaglutide safety penalty.
The distribution of serious adverse events also leaned in the same direction across several clinically important categories. Infections and infestations, cardiac disorders, respiratory, thoracic and mediastinal disorders, and metabolism and nutrition disorders were generally less frequent with semaglutide than with placebo, regardless of baseline kidney function. For a population in which infection, heart disease, and metabolic instability often drive deterioration, that consistency supports the idea that the drug’s overall physiologic effects did not become less manageable as renal function worsened.
Gastrointestinal intolerance remained the main practical hurdle
The clearest treatment-limiting signal came from gastrointestinal adverse events. Discontinuations due to adverse events increased as baseline eGFR declined in both groups, reflecting the clinical fragility of the lower-eGFR population. Among participants with eGFR of 60 or more mL/min/1.73 m2, discontinuation occurred in 11.2% of semaglutide-treated participants and 11.3% of placebo-treated participants. In those with eGFR below 30 mL/min/1.73 m2, discontinuation rose to 18.8% with semaglutide and 18.7% with placebo.
Discontinuation specifically because of gastrointestinal adverse events occurred more frequently with semaglutide than with placebo, and that pattern held across eGFR subgroups. The rates were 4.5% with semaglutide versus 1.1% with placebo. For practicing clinicians, this remains the dominant tolerability issue when initiating a glucagon-like peptide-1 receptor agonist in CKD: nausea, vomiting, early satiety, and related symptoms can erode adherence even when the medication is not producing kidney-specific toxicity.
The biological rationale fits the observed pattern. Semaglutide slows gastric emptying and alters appetite signaling, effects that can be therapeutically useful for glycemic control and weight reduction but also account for the gastrointestinal burden seen in trials and routine care. In patients with CKD, where volume depletion and poor oral intake can have outsized consequences, those symptoms deserve active monitoring even when renal safety appears reassuring.
Prespecified adverse events of special interest stayed comparable
Prespecified adverse events of special interest were similar between treatment groups across baseline eGFR categories. No unexpected safety concern emerged in the subgroup analysis, and the pattern did not suggest that reduced kidney function introduced a distinct class of harm related to semaglutide exposure. For nephrology practice, that is an important distinction. CKD often amplifies concern that any chronic medication may behave unpredictably, yet this dataset did not show a new safety signal tied to declining eGFR.
The findings also help place semaglutide in a more realistic therapeutic frame. The drug’s tolerability in CKD is not defined only by renal clearance, because the major challenge here is not accumulation of a nephrotoxic compound but the interplay between systemic illness burden and gastrointestinal side effects. In patients already living near the edge of dehydration, anorexia, or poor medication tolerance, even a generally safe therapy can become difficult to maintain without careful dose escalation, symptom review, and attention to hydration status.
What FLOW adds to daily nephrology care
This analysis strengthens confidence that semaglutide can be used across a broad range of kidney function without an emerging signal for excess serious toxicity. The lower rate of serious adverse events with semaglutide versus placebo across eGFR strata is reassuring, particularly because the sickest CKD patients are the ones in whom adverse-event concerns usually sharpen. The trade-off remains familiar: gastrointestinal intolerance, not kidney toxicity, is the main reason treatment can fail at the bedside.
One practical implication follows directly from these data. In patients with T2D and CKD, baseline eGFR alone should not be treated as a reason to expect a fundamentally different semaglutide safety profile. The more relevant issue is clinical tolerance, especially gastrointestinal symptoms and the downstream risk of poor intake or discontinuation.
The dataset is descriptive, and safety events were collected selectively rather than as the sole trial focus, so the analysis does not answer every question about mechanism or rare harms. Even so, the core message is durable: within FLOW, semaglutide remained usable across the CKD severity range studied, with no new safety concern emerging as eGFR declined.